Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients

Eisuke Kaji, Jun Kato, Shunsuke Saito, Keita Harada, Kenji Kuwaki, Masashi Tatsukawa, Tamiya Morikawa, Sakiko Hiraoka, Hiroshi Matsushima, Kazuhide Yamamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of folate and homocysteine on colon tumorigenesis by performing colonoscopy and examining serum folate and homocysteine levels in end-stage renal disease (ESRD) patients. We performed colonoscopy in 72 ESRD patients who were undergoing hemodialysis and also measured their serum folate and homocysteine levels. Serum folate and homocysteine concentrations of the 72 ESRD patients were 6.0 ± 3.9 μg/l and 37.3 ± 25.5 μmol/l, respectively. Colorectal neoplasia was detected in 47 (65%) of the patients. Compared to a control group, ESRD patients had significantly more and larger neoplasia (P = 0.002 and 0.001, respectively). Multivariate analysis revealed that ESRD patients with lower levels of serum homocysteine had significantly more and larger neoplasia than those with higher levels (P = 0.02 and 0.03, respectively). In addition, patients with a shorter duration of hemodialysis were likely to have larger neoplasia. ESRD patients had higher than normal serum homocysteine levels. Interestingly, patients with lower homocysteine levels were likely to carry more and larger colorectal neoplasia. These results suggest that suppression of folate metabolism and an elevated serum homocysteine concentration are inversely associated with colon tumorigenesis in ESRD patients.

Original languageEnglish
Pages (from-to)202-211
Number of pages10
JournalNutrition and Cancer
Volume63
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Homocysteine
Folic Acid
Chronic Kidney Failure
Colon
Carcinogenesis
Serum
Colonoscopy
Neoplasms
Renal Dialysis
Multivariate Analysis
Control Groups

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Oncology
  • Cancer Research

Cite this

Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients. / Kaji, Eisuke; Kato, Jun; Saito, Shunsuke; Harada, Keita; Kuwaki, Kenji; Tatsukawa, Masashi; Morikawa, Tamiya; Hiraoka, Sakiko; Matsushima, Hiroshi; Yamamoto, Kazuhide.

In: Nutrition and Cancer, Vol. 63, No. 2, 02.2011, p. 202-211.

Research output: Contribution to journalArticle

Kaji, E, Kato, J, Saito, S, Harada, K, Kuwaki, K, Tatsukawa, M, Morikawa, T, Hiraoka, S, Matsushima, H & Yamamoto, K 2011, 'Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients', Nutrition and Cancer, vol. 63, no. 2, pp. 202-211. https://doi.org/10.1080/01635581.2011.523501
Kaji, Eisuke ; Kato, Jun ; Saito, Shunsuke ; Harada, Keita ; Kuwaki, Kenji ; Tatsukawa, Masashi ; Morikawa, Tamiya ; Hiraoka, Sakiko ; Matsushima, Hiroshi ; Yamamoto, Kazuhide. / Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients. In: Nutrition and Cancer. 2011 ; Vol. 63, No. 2. pp. 202-211.
@article{e18d7f88082043d6be6e92bfb76a4a0b,
title = "Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients",
abstract = "The aim of this study was to evaluate the effect of folate and homocysteine on colon tumorigenesis by performing colonoscopy and examining serum folate and homocysteine levels in end-stage renal disease (ESRD) patients. We performed colonoscopy in 72 ESRD patients who were undergoing hemodialysis and also measured their serum folate and homocysteine levels. Serum folate and homocysteine concentrations of the 72 ESRD patients were 6.0 ± 3.9 μg/l and 37.3 ± 25.5 μmol/l, respectively. Colorectal neoplasia was detected in 47 (65{\%}) of the patients. Compared to a control group, ESRD patients had significantly more and larger neoplasia (P = 0.002 and 0.001, respectively). Multivariate analysis revealed that ESRD patients with lower levels of serum homocysteine had significantly more and larger neoplasia than those with higher levels (P = 0.02 and 0.03, respectively). In addition, patients with a shorter duration of hemodialysis were likely to have larger neoplasia. ESRD patients had higher than normal serum homocysteine levels. Interestingly, patients with lower homocysteine levels were likely to carry more and larger colorectal neoplasia. These results suggest that suppression of folate metabolism and an elevated serum homocysteine concentration are inversely associated with colon tumorigenesis in ESRD patients.",
author = "Eisuke Kaji and Jun Kato and Shunsuke Saito and Keita Harada and Kenji Kuwaki and Masashi Tatsukawa and Tamiya Morikawa and Sakiko Hiraoka and Hiroshi Matsushima and Kazuhide Yamamoto",
year = "2011",
month = "2",
doi = "10.1080/01635581.2011.523501",
language = "English",
volume = "63",
pages = "202--211",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "2",

}

TY - JOUR

T1 - Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients

AU - Kaji, Eisuke

AU - Kato, Jun

AU - Saito, Shunsuke

AU - Harada, Keita

AU - Kuwaki, Kenji

AU - Tatsukawa, Masashi

AU - Morikawa, Tamiya

AU - Hiraoka, Sakiko

AU - Matsushima, Hiroshi

AU - Yamamoto, Kazuhide

PY - 2011/2

Y1 - 2011/2

N2 - The aim of this study was to evaluate the effect of folate and homocysteine on colon tumorigenesis by performing colonoscopy and examining serum folate and homocysteine levels in end-stage renal disease (ESRD) patients. We performed colonoscopy in 72 ESRD patients who were undergoing hemodialysis and also measured their serum folate and homocysteine levels. Serum folate and homocysteine concentrations of the 72 ESRD patients were 6.0 ± 3.9 μg/l and 37.3 ± 25.5 μmol/l, respectively. Colorectal neoplasia was detected in 47 (65%) of the patients. Compared to a control group, ESRD patients had significantly more and larger neoplasia (P = 0.002 and 0.001, respectively). Multivariate analysis revealed that ESRD patients with lower levels of serum homocysteine had significantly more and larger neoplasia than those with higher levels (P = 0.02 and 0.03, respectively). In addition, patients with a shorter duration of hemodialysis were likely to have larger neoplasia. ESRD patients had higher than normal serum homocysteine levels. Interestingly, patients with lower homocysteine levels were likely to carry more and larger colorectal neoplasia. These results suggest that suppression of folate metabolism and an elevated serum homocysteine concentration are inversely associated with colon tumorigenesis in ESRD patients.

AB - The aim of this study was to evaluate the effect of folate and homocysteine on colon tumorigenesis by performing colonoscopy and examining serum folate and homocysteine levels in end-stage renal disease (ESRD) patients. We performed colonoscopy in 72 ESRD patients who were undergoing hemodialysis and also measured their serum folate and homocysteine levels. Serum folate and homocysteine concentrations of the 72 ESRD patients were 6.0 ± 3.9 μg/l and 37.3 ± 25.5 μmol/l, respectively. Colorectal neoplasia was detected in 47 (65%) of the patients. Compared to a control group, ESRD patients had significantly more and larger neoplasia (P = 0.002 and 0.001, respectively). Multivariate analysis revealed that ESRD patients with lower levels of serum homocysteine had significantly more and larger neoplasia than those with higher levels (P = 0.02 and 0.03, respectively). In addition, patients with a shorter duration of hemodialysis were likely to have larger neoplasia. ESRD patients had higher than normal serum homocysteine levels. Interestingly, patients with lower homocysteine levels were likely to carry more and larger colorectal neoplasia. These results suggest that suppression of folate metabolism and an elevated serum homocysteine concentration are inversely associated with colon tumorigenesis in ESRD patients.

UR - http://www.scopus.com/inward/record.url?scp=79951929509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951929509&partnerID=8YFLogxK

U2 - 10.1080/01635581.2011.523501

DO - 10.1080/01635581.2011.523501

M3 - Article

C2 - 21264789

AN - SCOPUS:79951929509

VL - 63

SP - 202

EP - 211

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 2

ER -